The identification of myostatin as a potential target for SMA treatment and the clinical benefit of apitegromab has led to the development of other therapies targeting myostatin as well as phase 3 trials of combination therapy with nusinersen or risdiplam (Day et al., 2022). Here, MSTN is linked to proximal spinal muscular atrophy.